Pharmacodynamic endpoints: ≥20–30% shortening of CD8+–tumor distances, ≥30% reduction of continuous macrophage/CAF–tumor interfaces, and ≥1-grade HLA-I upshift with emergence of tumor–immune interdigitation; biopsy at baseline and ~2–4 weeks on-treatment. Here, CD8A is linked to neoplasm.